Sugi Predict

Sugi Predict / Compounds / SCHEMBL1779819

SCHEMBL1779819

SCHEMBL1779819

Cc1nn(-c2ccccc2)c(C)c1C=O

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.64
▸ ALOX15 P16050 1/20 0.64
▸ LMNA P02545 1/20 0.63
▸ KMT2A Q03164 3/20 0.59
▸ MEN1 O00255 2/20 0.59
▸ KDM4E B2RXH2 2/20 0.58
▸ POLB P06746 1/20 0.58
▸ APEX1 P27695 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ KDM4C Q9H3R0 1/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ MAPT P10636 3/20 0.54
▸ GAA P10253 1/20 0.54
▸ ALDH1A1 P00352 4/20 0.53
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27875396 0.86 ALDH1A1 (0.49) HTTALOX15LMNAKMT2AMEN1
SCHEMBL3321050 0.84 HTT (0.47) HTTALOX15LMNAKMT2AMEN1
SCHEMBL1267498 0.83 SMN1; SMN2 (0.66) HTTLMNAKMT2AMEN1KDM4E
SCHEMBL8883561 0.83 LMNA (0.60) HTTALOX15LMNAKMT2AMEN1
SCHEMBL13739457 0.83 MAPT (0.51) HTTALOX15LMNAKMT2AMEN1
SCHEMBL4239043 0.83 NPC1 (0.49) HTTALOX15LMNAKMT2AMEN1
SCHEMBL8883850 0.83 LMNA (0.60) HTTALOX15LMNAKMT2AMEN1
SCHEMBL3835167 0.83 HTT (0.64) HTTALOX15LMNAKMT2AMEN1
SCHEMBL29956682 0.83 LMNA (0.60) HTTALOX15LMNAKMT2AMEN1
SCHEMBL27950463 0.83 LMNA (0.50) HTTALOX15LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112368279-B Novel compounds as mTOR inhibitors and uses thereof 医药生命融合研究团 2024-05-28 — — CN disclosed
CN-118084918-A Chemiluminescent probe, preparation method thereof and application thereof in detection of beta amyloid 中国药科大学 2024-05-28 — — CN disclosed
US-11649231-B2 Compound as mTOR inhibitor and use thereof MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) 2023-05-16 — — US disclosed
US-20210292314-A1 NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) 2021-09-23 — — US disclosed
EP-3786163-A1 NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF Medicinal Bioconvergence Research Center (KR) 2021-03-03 — — EP disclosed
CN-112368279-A Novel compounds as mTOR inhibitors and uses thereof 医药生命融合研究团 2021-02-12 — — CN disclosed
US-10160756-B2 Antiviral compounds and methods using same THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-12-25 — — US disclosed
US-20170174678-A1 NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME Rhe Trustees of The University of Pennsylvania 2017-06-22 — — US disclosed
EP-3126005-A1 NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME The Trustees Of The University Of Pennsylvania (US) 2017-02-08 — — EP disclosed
CN-104478804-B Double nitrogen-containing heterocycle compounds and its preparation method and application 河南大学 2016-08-17 — — CN disclosed
CN-1289326-A N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia PFIZER PROD INC (US) 2001-03-28 — — CN disclosed
WO-2000064959-A1 COMPOSITION COMPRISING MERCAPTO-FUNCTIONAL COMPOUNDS AKZO NOBEL N.V. (NL) 2000-11-02 — — WO disclosed
US-5773456-A EMPHYSEMA, RHEUMATOID ARTHRITIS AND PANCREATITIS SANOFI (FR) 1998-06-30 — — US disclosed
US-5464852-A Used in treatment of degenerative diseases STERLING WINTHROP INC. (US) 1995-11-07 — — US disclosed
US-5380737-A Enzyme inhibitors STERLING WINTHROP INC. (US) 1995-01-10 — — US disclosed
EP-0542371-A1 Saccharin derivative proteolytic enzyme inhibitors STERLING WINTHROP INC. (US) 1993-05-19 — — EP disclosed
US-5068345-A Oxazolidinone aldol adduct EASTMAN KODAK COMPANY (US) 1991-11-26 — — US disclosed
US-5049483-A Containing a 2-mercapto (benz) imidazole or a (benzo) triazole compound as antistatic agent KONICA CORPORATION (JP) 1991-09-17 — — US disclosed
US-5012000-A Total synthesis of chiral 2-amino-1,3-diols EASTMAN KODAK COMPANY (US) 1991-04-30 — — US disclosed
EP-0401846-A2 A direct positive silver halide photographic light-sensitive material and a processing method therefor KONICA CORPORATION (JP) 1990-12-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649231-B2 Compound as mTOR inhibitor and use thereof MTOR, RICTOR, RPTOR HTT 517/4885ALOX15 1673/4885LMNA 3962/4885
US-20170174678-A1 NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME ZC3HAV1, MAVS, ZC3HAV1L HTT 4090/4885ALOX15 727/4885LMNA 2215/4885
US-10160756-B2 Antiviral compounds and methods using same ZC3HAV1, MAVS, ZC3HAV1L HTT 2954/4885ALOX15 767/4885LMNA 2151/4885
US-20210292314-A1 NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF MTOR, RICTOR, RPTOR HTT 776/4885ALOX15 1834/4885LMNA 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.